Prostaglandins & Other Lipid Mediators: review time and acceptance speed
ISSN 1098-8823 · ISSN 2212-196X · Elsevier BV · Biochemistry, Genetics and Molecular Biology
Half of the articles Prostaglandins & Other Lipid Mediators accepted in 2024 were accepted within 83 days of submission (n = 90); the middle half took 57–131 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Prostaglandins & Other Lipid Mediators take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2024 | 90 | 57 | 83 | 131 | — | 0.0% | 98% |
| 2023 | 58 | 62 | 82 | 127 | — | 0.0% | 98% |
| 2020 | 55 | 98 | 154 | 220 | — | 0.0% | 100% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Distribution in 2024
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 6 | 6.7% |
| 30–59 | 19 | 21.1% |
| 60–89 | 25 | 27.8% |
| 90–119 | 12 | 13.3% |
| 120–149 | 16 | 17.8% |
| 150–179 | 8 | 8.9% |
| 180–209 | 1 | 1.1% |
| 210–239 | 3 | 3.3% |
| 240–269 | 0 | 0.0% |
| 270–299 | 0 | 0.0% |
| 300–329 | 0 | 0.0% |
| 330–359 | 0 | 0.0% |
| 360+ | 0 | 0.0% |
From acceptance to online publication
After acceptance, half of the 2024 articles appeared online within 3 days (middle half 1–6 days, n = 90).
From submission to online publication, the median was 89 days (middle half 60–133 days, n = 90).
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Hybrid (subscription journal with an open-access option). Listed APC: about $3,500 (as reported by OpenAlex).
OpenAPC has fewer than 5 reported payments for this journal in 2023–2025, so no typical amount is shown.
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | No |
|---|---|
| Articles indexed for MEDLINE in 2024 | Yes |
| Retractions | 0 retracted articles among 272 added to PubMed in 2021–2025 (0.00 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 0.0% of 2024 articles |
| Publication volume | 89 articles added to PubMed in 2024 (+53% vs 2023). |
Topics and scope
- Inflammatory mediators and NSAID effects (16% of indexed topics)
- Eicosanoids and Hypertension Pharmacology (15% of indexed topics)
- Estrogen and related hormone effects (7% of indexed topics)
- Fatty Acid Research and Health (6% of indexed topics)
- Peroxisome Proliferator-Activated Receptors (5% of indexed topics)
- Sphingolipid Metabolism and Signaling (4% of indexed topics)
Biochemistry, Genetics and Molecular Biology journalsMedicine journals
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2024 figures are compared with the 2024 median of Prostaglandins & Other Lipid Mediators, 83 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| Inflammopharmacology | 57 (2024, n = 219) | ≈$4,990 | — | No | Yes |
| Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | 121 (2024, n = 92) | ≈$3,670 | — | No | Yes |
| Vascular Pharmacology | 72 (2024, n = 63) | ≈$3,670 | — | No | Yes |
| Pharmacological Research | 86 (2024, n = 411) | $4,510 | $4,105 (6 payments) | Yes | Yes |
| Biochemical Pharmacology | 114 (2024, n = 558) | ≈$3,590 | — | No | Yes |
| Inflammation Research | 91 (2024, n = 136) | ≈$4,790 | — | No | Yes |
| Pharmacology & Therapeutics | 126 (2024, n = 106) | ≈$5,660 | — | No | Yes |
No journals match these filters.
Frequently asked questions
How long does Prostaglandins & Other Lipid Mediators take to accept a paper?
Half of the articles Prostaglandins & Other Lipid Mediators accepted in 2024 were accepted within 83 days of submission (n = 90); the middle half took 57–131 days. Based on dates in PubMed for accepted articles only.
How long after acceptance are Prostaglandins & Other Lipid Mediators articles published online?
Half of the articles accepted in 2024 appeared online within 3 days of acceptance (n = 90).
Does Prostaglandins & Other Lipid Mediators charge an article processing charge (APC)?
Listed APC: about $3,500 (as reported by OpenAlex).
Sources and method
Journal identity: ISSN-L 1098-8823; NLM ID 9808648; OpenAlex record. Speed figures use 90 articles accepted in 2024 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.